A Phase 1 interventional study of Gamma-PN in Pneumococcal Disease, Invasive and Pneumococcal Disease, sponsored by GPN Vaccines. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-03.
Sponsored by GPN Vaccines · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Pneumococcal Infections with a site in Australia — 3 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal Infections · Australia.
Among the 16 studies in Pneumococcal Infections with a site in Australia, this one is the 16th largest by planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 1, and was the 15th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →3 of the 16 studies in Pneumococcal Infections with a site in Australia are open now. Recruiting first, the newest first:
Pfizer · Sites in Australia, United States, Argentina and 8 more countries
Ages 42 days–98 days · Healthy volunteers
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Sites in Australia
Ages 60+ · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 69 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 1 · Phase 3 12
First in 2006; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 12 is below the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 851 across the 16 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 16 have an industry lead sponsor. The 6 most frequent:
GPN Vaccines is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
GPN Vaccines has 3 studies filed under Pneumococcal Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Pneumococcal Infections with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation
The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation
Participants will receive a dose of Gamma-PN and serum will be collected pre dose and Day 28
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intramuscular administration 500 mcg
Biological: Gamma-PN
Killed whole-cell pneumococcal vaccine
OPA
Opsonophagocytic assay
Time frame: 6 months
Start is estimated for Oct 2025; primary completion for Jan 2026, 3 months later.
Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's planned 3 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GPN Vaccines